Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

This letter describes the development of two series of potent and selective allosteric Akt kinase inhibitors that display an unprecedented level of selectivity for either Akt1, Akt2 or both Akt1/Akt2. An iterative analog library synthesis approach quickly provided a highly selective Akt1/Akt2 inhibitor that induces apoptosis in tumor cells and inhibits Akt phosphorylation in vivo.

[1]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[2]  Qun Li,et al.  Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. , 2002, Current topics in medicinal chemistry.

[3]  C. Lindsley,et al.  General microwave-assisted protocols for the expedient synthesis of quinoxalines and heterocyclic pyrazines , 2004 .

[4]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Franke,et al.  Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses , 2002, Oncogene.

[6]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Graff.  Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma , 2002, Expert opinion on therapeutic targets.

[8]  N. Guseva,et al.  Caspase‐8 activation is necessary but not sufficient for tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐mediated apoptosis in the prostatic carcinoma cell line LNCaP , 2002, The Prostate.

[9]  C. Lindsley,et al.  Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries. , 2003, Journal of combinatorial chemistry.

[10]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[11]  Jiayuh Lin,et al.  Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. , 2000, Anticancer research.

[12]  P. Dennis,et al.  Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. , 2003, Journal of the American Chemical Society.

[13]  Z. Lu,et al.  AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  R. Huber,et al.  Structure-based optimization of novel azepane derivatives as PKB inhibitors. , 2004, Journal of medicinal chemistry.

[15]  C. Lindsley,et al.  Fluorous-tethered quenching reagents for solution phase parallel synthesis , 2002 .

[16]  Wei Zhang,et al.  Use of fluorous silica gel to separate fluorous thiol quenching derivatives in solution-phase parallel synthesis , 2002 .

[17]  Arthur A. Patchett,et al.  Chapter 26. Privileged structures — An update , 2000 .

[18]  Gordon Mills,et al.  Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC , 1998, Current Biology.